12:00 AM
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Invokana canagliflozin: Additional Phase III data

Additional data from the double-blind, international Phase III CANTATA-SU (DIA3009) trial in 1,450 Type II diabetics with inadequate glycemic control on maximally effective doses of metformin showed that once-daily 100 and 300 mg oral canagliflozin each led to a greater reduction in HbA1c from baseline to week 104 vs. glimepiride (0.65% and 0.74%, respectively, vs. 0.55%). Additionally, both doses of canagliflozin led to greater reductions in...

Read the full 308 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >